DNA vs PRME: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

DNA (Ginkgo Bioworks Holdings) and PRME (Prime Medicine) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.

DNA vs PRME: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricDNAPRMEWhat it tells you
Market cap$805.73M$708.28MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-4.13-4.32Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.742.15Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range51% of range38% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.9517.36How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how DNA and PRME affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DNA and PRME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DNA and PRME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Ginkgo Bioworks Holdings (DNA) do?

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic-biology company built around a horizontal cell-programming platform. Historically it reported in two segments: Cell Engineering, where its automated Foundry labs and Datapoints data service engineer and characterize cells for pharma, agriculture, food, and industrial customers; and Biosecurity, which provided pathogen monitoring and bioinformatics to governments and institutions. Cell Engineering revenue is generated through R&D service fees, its Datapoints biological-data offerings, and design, build, and support fees for its lab-automation (RAC) systems. Ginkgo went public via SPAC in 2021 at a lofty valuation that has since collapsed.

Full DNA guide

What does Prime Medicine (PRME) do?

Prime Medicine is a gene-editing company developing therapies based on prime editing, a technology that pairs a CRISPR-derived nickase with a reverse transcriptase to make targeted search-and-replace edits to DNA without cutting both strands. The platform is positioned to address a broad range of genetic mutations and to deliver one-time treatments, but as of 2026 the company has no approved products and no product revenue. Its economics are typical of clinical-stage biotech: heavy research and development spending, recurring net losses, and reliance on cash reserves, partnerships, and equity raises to fund operations. The second half of 2026 moved the story from preclinical to clinical: the FDA cleared the Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency on September 24, 2026, and the first patient was dosed in a global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson Disease on October 5, 2026. In Q2 2026 the company reported ~$1.15 million of collaboration revenue and a ~$42.1 million net loss (EPS ~-$0.24 versus a ~-$0.26 estimate). The shares rose ~11.2% over the month to October 16, 2026, closing at ~$3.47, but remain down ~1.7% for the year and ~40.2% over twelve months.

Full PRME guide

DNA vs PRME: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • DNA drivers: AI, autonomous labs, and Datapoints; Cost restructuring toward breakeven.
  • PRME drivers: Narrowed focus on a liver franchise; Lead asset and FDA engagement.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived. For PRME, prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial.

DNA or PRME: which should you pick?

Pick DNA if you believe its drivers more; PRME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DNA and PRME guides.

DNA vs PRME: the full fundamentals

DNA. Ginkgo trades at about 5.4 times trailing sales with no earnings, so the valuation rests on whether revenue stabilizes near the ~$20 million quarterly run rate and losses keep shrinking toward the breakeven target. The stock is up about 21% in 2026 and about 34% over the past month on autonomous-lab and Datapoints news, but it remains down about 30% over the past year and sits well below its 52-week high of $18.22. Figures are from Yahoo Finance as of October 16, 2026; verify live numbers before acting.

PRME. Prime Medicine is not profitable and is valued on its pipeline rather than earnings; a price-to-sales ratio near ~155x on collaboration revenue says little. The relevant numbers are cash against burn and the timing of the first clinical data from PM577a and PM647, which entered the clinic in September and October 2026. Figures are approximate as of October 16, 2026; check the latest filings for current numbers.

Headline figures (approximate, October 2026): DNA shows revenue (ttm) ~$132 million, with Q2 2026 revenue of ~$20 million down ~48% year over year, gross margin ~68%, while operating margin is deeply negative at about -285%, net loss (ttm) ~$310 million; Q2 2026 loss narrowed to ~$47 million from ~$83 million in Q1, eps (ttm / forward) ~-$5.06 trailing; consensus ~-$2.93 for 2026; PRME shows product revenue None; collaboration revenue ~$4.1 million trailing twelve months (~$1.15 million in Q2 2026), net loss ~$187.9 million trailing; Q2 2026 net loss ~$42.1 million (EPS ~-$0.24 versus a ~-$0.26 estimate), cash and debt (june 30, 2026) ~$95.1 million cash and equivalents against ~$112.5 million of debt, cash burn Operating cash flow ~-$156 million trailing twelve months.

The bottom line: DNA vs PRME

DNA and PRME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DNA and PRME exposure against your real portfolio. It is not an investment adviser.

Wondering how DNA or PRME fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Ginkgo Bioworks Holdings

Ask Walnut's AI anything about DNA and see how it fits what you own.

FAQ

What is the difference between DNA and PRME?

+

Ginkgo Bioworks Holdings, Inc. Prime Medicine is a gene-editing company developing therapies based on prime editing, a technology that pairs a CRISPR-derived nickase with a reverse transcriptase to make targeted search-and-replace edits to DNA without cutting both strands. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is DNA or PRME the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, DNA or PRME?

+

On forward P/E (as of November 2026), DNA trades at -4.13x and PRME at -4.32x, so PRME is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both DNA and PRME?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of DNA vs PRME?

+

DNA: The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived. If losses persist, further capital raises could dilute existing shareholders, and the company already completed a 1-for-40 reverse split after its post-SPAC valuation collapsed by billions, a reminder of how far expectations have reset. Customer concentration is a concern because a handful of large partners can drive results, and losing or delaying programs hits revenue hard. Competition spans synthetic-biology, lab-automation, and bio-AI players with more focus or funding. Execution risk on the autonomous-lab pivot is high, and the stock is speculative and volatile, so outcomes could be very good or very poor. Wall Street coverage is thin and skeptical: the two analysts in the Yahoo Finance consensus rate it underperform with a mean target near $8, below the October 16 close of $10.53. PRME: Prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. As of March 31, 2026 the company reported roughly ~$149.2 million in cash, cash equivalents, investments, and restricted cash, which management expected to fund operations into 2027; by June 30, 2026 cash and equivalents stood near ~$95.1 million against ~$112.5 million of debt, and trailing operating cash burn was ~$156 million, implying that another financing will likely be needed and could dilute existing shareholders. Lead programs only entered the clinic in September and October 2026, so a failed readout, a delayed filing, or a safety setback could materially reduce the company's value. It also competes with better-capitalized gene-editing peers, some of which already have approved or later-stage products. Sentiment across gene editing is also volatile: in late September 2026 PRME, CRSP, NTLA, BEAM and EDIT all slipped on reports about AI-driven discovery tools before rebounding.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DNA or PRME; figures are approximate and dated (as of November 2026). Verify current data before investing.